Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes

cDNAs encoding functional T cell receptor (TCR) α and β chains from a CD4+ T cell line (SG6) generated by repeated stimulation of a melanoma patient's peripheral blood mononuclear cells with HLA-DP4–restricted, NY-ESO-1–specific peptide p161-180 were cloned using a 5′rapid amplification of cDNA end method. Three different TCR α chains and 7 TCR β chains were found among the 84 α and 162 β cDNA clones tested. By screening different combination of the α/β chains using RNA electroporation, TRAV9-1 (Vα22.1) and TRBV20-1 (Vβ2) were found to be the functional pair in line SG6. Antibody blocking experiments confirmed that the specificity of TRAV9-1/TRBV20-1 mRNA-transfected T cells were CD4 dependent and HLA-DP4 restricted. A retroviral vector expressing both TRAV9-1 and TRBV20-1 was constructed and used for transduction of OKT3-stimulated peripheral blood lymphocytes from melanoma patients. TCR-transduced CD4 T cells were capable of recognizing peptide-pulsed antigen-presenting cells (Epstein-Barr virus transformed B-cells, dendritic cells, and peripheral blood mononuclear cells), and protein-pulsed dendritic cells. Transduced cells were also capable of proliferation upon peptide stimulation and recognized peptide concentrations that were recognized by the parental line (0.2 μM). In contrast to SG6, which could not recognize human tumors, TCR-transduced CD4 T cells could specifically recognize NY-ESO-1/HLA-DP4–expressing melanoma cells. Major histocompatibility complex class II TCR-transduced CD4 T cells provides an alternative source of tumor antigen-specific T cells for adoptive immunotherapy of cancer patients.

[1]  S. Rosenberg,et al.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  A. Trautmann,et al.  Multiple survival signals are delivered by dendritic cells to naive CD4+ T cells , 2005, European journal of immunology.

[3]  S. Rosenberg,et al.  Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples , 2005, Journal of immunotherapy.

[4]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[5]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Richard A. Morgan,et al.  Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.

[7]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[8]  Pedro Romero,et al.  Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.

[9]  S. Rosenberg,et al.  Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen , 2004, Journal of immunotherapy.

[10]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Melcher,et al.  A simple method to cure established tumors by inflammatory killing of normal cells , 2004, Nature Biotechnology.

[12]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[13]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[14]  P. Cresswell,et al.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids , 2004, Immunogenetics.

[15]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[16]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[18]  Yao-Tseng Chen,et al.  A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. , 2002, Gene.

[19]  A. Lokshin,et al.  Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. , 2002, International immunology.

[20]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Sidney,et al.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. , 2002, Cancer research.

[22]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[23]  V. Brusic,et al.  NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. , 2002, Cancer research.

[24]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[25]  E. Shevach,et al.  Control of T‐cell activation by CD4+ CD25+ suppressor T cells , 2001, Immunological reviews.

[26]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[27]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[28]  S. Rosenberg,et al.  CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Matsushita,et al.  Monocytes Are Differentially Activated Through HLA-DR, -DQ, and -DP Molecules Via Mitogen-Activated Protein Kinases1 , 2001, The Journal of Immunology.

[30]  U. Grohmann,et al.  Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo1 , 2000, The Journal of Immunology.

[31]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. H. van der Burg,et al.  Importance of CD4(+) T helper cell responses in tumor immunity. , 2000, Immunology letters.

[33]  E. Bröcker,et al.  MHC class II and CD40 play opposing roles in dendritic cell survival , 2000, European journal of immunology.

[34]  S. Rosenberg,et al.  Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.

[35]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Restifo,et al.  Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen , 2000, The Journal of Immunology.

[37]  G. Plautz,et al.  CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. , 2000, Critical reviews in immunology.

[38]  Jonathan J. Lewis,et al.  Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.

[39]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[40]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[41]  D. Jäger,et al.  Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.

[42]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[43]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[45]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[46]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[47]  L. Michaux,et al.  LAGE‐1, a new gene with tumor specificity , 1998, International journal of cancer.

[48]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[49]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Schuler,et al.  High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 [published erratum appears in J Exp Med 1996 Oct 1;184(4):following 1590] , 1996, The Journal of experimental medicine.

[51]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[52]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[53]  R. North Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[54]  R. Gershon A Disquisition on Suppressor T Cells , 1975, Transplantation reviews.